Published November 2, 2026 · Historical safety information explained
Three dates can describe different events
A medicine webpage can be updated without a newly discovered risk. For example, the ScieGen gabapentin label on DailyMed shows an October 23, 2026 update and a July 2026 revision date, while its recent-major-changes table identifies April 2025 warning changes. Those dates alone do not demonstrate a new October dementia warning.
Check the underlying FDA record
The Drugs@FDA Neurontin capsule approval history lists an April 25, 2025 labeling action. The linked April 2025 prescribing information addresses risks with rapid discontinuation, including seizures, withdrawal symptoms and observed suicidal behavior or thoughts after discontinuation. This is historical labeling, not a newly issued November 2026 alert.
Breathing warnings have their own history
The FDA breathing-risk communication was posted December 19, 2019. It concerns both gabapentin products and the distinct medicine pregabalin, particularly with opioids, other central nervous system depressants or underlying respiratory impairment. A recent article discussing that communication does not make it a new warning. See our breathing-risk guide.
Keep the information supplied with your prescription
Retain the medication guide, pharmacy label and dispensing dates if available. For a legal review, the warnings supplied during your treatment matter alongside the medical record. Do not change or stop prescribed treatment based on a headline. Ask your prescriber about concerns, and see our withdrawal guide for safety context. A label warning does not itself establish liability or an entitlement to compensation.
